drugset / Trial / NCT01294878
Omalizumab in Interstitial Cystitis/Bladder Pain Syndrome
NaSingle-groupOpen-labelTreatment
Summary
By hypothesising that Interstitial Cystitis is an allergic disorder of the urogenital system that is linked to mast-cells, current therapy with omalizumab may represent a potential non symptomatic strategy for the treatment of IC/BPS
Timeline
- Start
- 2009-03
- Primary completion
- 2010-09
- Completion
- 2010-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Omalizumab | Monoclonal antibody | 150 mg | Subcutaneous |
| Subject | Omalizumab | Monoclonal antibody | 300 mg | Subcutaneous |
| Subject | Omalizumab | Monoclonal antibody | 450 mg | Subcutaneous |